Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5974
    -0.0002 (-0.03%)
     
  • NZD/EUR

    0.5539
    +0.0006 (+0.11%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • NZD/JPY

    90.3710
    -0.0220 (-0.02%)
     

US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

ReportLinker
ReportLinker

Report Highlights:. • Research Methodology. • US Transdermal Patch Market Opportunity > USD 9 Billion. • Market Availability, Dosage & Price Analysis On FDA Approved Patches.

New York, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028" - https://www.reportlinker.com/p06325624/?utm_source=GNW
• US Transdermal Patch Market Opportunity Assessment By Indication
• US Transdermal Patch Clinical Pipeline Clinical Insight by Company, Drug Class, Indication & Phase
• Comprehensive Insight On Approved Patches In Clinical Trials: > 40 Patch
• Transdermal Patch Patent Insight
• Insight On Marketed Transdermal Patch: > 30 FDA Approved Patch

Transdermal drug delivery which involves the delivery of drug into the systemic circulation across the skin has attracted physicians as well as patients owing to their several conferred advantages. These provide a specific, predetermined dose of medication which is absorbed through the skin into the bloodstream. In addition, it also improves patient compliance; eliminate the hepatic first pass, and degradation in gastrointestinal tract. Over the last 30 years, many transdermal products have been launched in the US market and the demand has been grown as more and more example of successful treatment enters the mainstream.

These patches deliver drugs tropically, where they are absorbed by the skin and into the bloodstream. These provide a consistent delivery of small amounts of a drug into the bloodstream over a long period of time. The length of wear time and the amount of drug delivered is different from patch to patch. To date, around 30 transdermal patches have entered the US market which is indicated for the management of wide range of diseases including cardiovascular diseases, neurological disorders, hormonal therapy, and other therapeutic conditions. Apart from this, several others are present in clinical trials, which are expected to enter the market during the forecast period.

As with any drug delivery system, there exists the potential for side effects with transdermal patches also which restrains their growth in market. The most likely side effect of a transdermal patch is irritated skin. Some wearers may have sensitive skin, making them more vulnerable to a reaction. Sensitivity can also result from the drug itself or the dose being too high. Apart from this, the high cost associated with the development of novel drug patch combination is anticipated to limit the investments in transdermal patches.

The US transdermal skin patch market is moderately competitive and the key players are focused on the adoption of various strategies including product innovation, product launches, and approvals. In addition, companies have also adopted collaboration, merger, and acquisitions as their development strategies to sustain the competitive environment in market. For instance, Canoa, a Delaware-based healthcare and pharmaceuticals company, had acquired ProSolus to enhance its position and development of new products in the transdermal space. The rising research and development activities in this field will propel the growth of market.

As per our report findings, the US transdermal patch market is expected to reach US$ 9 Billion by 2028. Increasing demand for painless drug delivery, coupled with ease of self administration of drugs, is anticipated to fuel market growth. The market is also propelled by ongoing technological advancements in the field. Smart patches, for instance, allow auto-injection of medication and help in monitoring various body parameters. They also enable the transmission of patient generated data, thereby improving timing and accuracy of drug administration. Furthermore, collaboration between pharmaceutical companies and drug delivery technology developers and preference for easy to use self administered drug delivery systems will create new market opportunities in coming years.

The report US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028 provides detailed analysis on the approved marketed products along with their price, dosage, and patch availability. The insights into ongoing clinical trials by company, drug class, indication, and phase are also reported. The major players covered in the US transdermal patches market report are AbbVie, Amneal Pharmaceuticals, Cumberland Pharmaceuticals, Glaxosmithkline, Hisamitsu Pharmaceutical and several others. On the basis of indication, the market opportunity is segmented into Alzheimer, Parkinson, Nicotine Replacement Therapy, Insulin, Vaccine, and Cardiovascular Disease.
Read the full report: https://www.reportlinker.com/p06325624/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001